Ganglioside GM1 and its semisynthetic lysogangliosides reduce glutamate neurotoxicity by a novel mechanism.
Costa
E
E
Fidia-Georgetown Institute for the Neurosciences, Washington, D.C. 20007.
Armstrong
D
D
Guidotti
A
A
Kharlamov
A
A
Kiedrowski
L
L
Wroblewski
J T
JT
D000818:Animals; D002118:Calcium / Q000378:metabolism; D002490:Central Nervous System / Q000187:drug effects* / Q000473:pathology / Q000502:physiology; D018691:Excitatory Amino Acid Antagonists; D005677:G(M1) Ganglioside / Q000494:pharmacology*; D005732:Gangliosides / Q000138:chemical synthesis / Q000494:pharmacology*; D005971:Glutamates / Q000633:toxicity*; D018698:Glutamic Acid; D006801:Humans; D009498:Neurotoxins / Q000037:antagonists & inhibitors / Q000633:toxicity*; D011110:Polymorphism, Genetic; D017470:Receptors, Glutamate / Q000737:chemistry / Q000235:genetics / Q000502:physiology*; D015290:Second Messenger Systems; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology; D009435:Synaptic Transmission / Q000187:drug effects / Q000502:physiology
D018691:Excitatory Amino Acid Antagonists; D005732:Gangliosides; D005971:Glutamates; D009498:Neurotoxins; D017470:Receptors, Glutamate; D005677:G(M1) Ganglioside; D018698:Glutamic Acid; D002118:Calcium